Study finds limited incidence of glycemic excursions in patients with TED treated with teprotumumab
Serious glycemic excursions are uncommon in patients with thyroid eye disease (TED) who receive teprotumumab therapy, particularly in those who are normoglycemic before treatment, according to a new study.
The study indicates that patients with controlled diabetes or impaired glucose tolerance can be safely treated with teprotumumab, as long as there is baseline screening, regular monitoring of glycemic control, and appropriate treatment of hyperglycemia.
The data also suggest that hyperglycemic incidents, when they occurred, were mostly in patients with baseline prediabetes or diabetes and were effectively controlled with medication.
Importantly, there was no evidence of progression or increased incidence of hyperglycemia with subsequent doses of teprotumumab.
Reference
Smith TJ, Cavida D, Hsu K, et al. Glycemic Trends in Thyroid Eye Disease (TED) Patients Treated with Teprotumumab in 3 Clinical Trials. Ophthalmology. 2024;S0161-6420(24)00082-4. doi: 10.1016/j.ophtha.2024.01.023. Epub ahead of print. PMID: 38253291.
Related Content
